| Literature DB >> 27932062 |
Hossein Amini-Khoei1, Shayan Amiri2, Ali Mohammadi-Asl3, Sakineh Alijanpour4, Simin Poursaman3, Arya Haj-Mirzaian5, Mojgan Rastegar2, Azam Mesdaghinia6, Hamid Reza Banafshe7, Ehsanollah Sadeghi8, Elika Samiei3, Shahram Ejtemaie Mehr5, Ahmad Reza Dehpour9.
Abstract
Early-life stress adversely affects the development of the brain, and alters a variety of behaviors such as pain in later life. In present study, we investigated how early-life stress (maternal separation or MS) can affect the nociceptive response later in life. We particularly focused on the role of oxytocin (OT) in regulating nociception in previously exposed (MS during early postnatal development) mice that were subjected to acute stress (restraint stress or RS). Further, we evaluated whether such modulation of pain sensation in MS mice are regulated by shared mechanisms of the OTergic and opioidergic systems. To do this, we assessed the underlying systems mediating the nociceptive response by administrating different antagonists (for both opioid and OTergic systems) under the different experimental conditions (control vs MS, and control plus RS vs MS plus RS). Our results showed that MS increased pain sensitivity in both tail-flick and hot-plate tests while after administration of OT (1μg/μl/mouse, i.c.v) pain threshold was increased. Atosiban, an OT antagonist (10μg/μl/mouse, i.c.v) abolished the effects of OT. While acute RS increased the pain threshold in control (and not MS) mice, treating MS mice with OT normalized the pain response to RS. This latter effect was reversed by atosiban and/or naltrexone, an opioid antagonist (0.5μg/μl/mouse, i.c.v) suggesting that OT enhances the effect of endogenous opioids. OTergic system is involved in mediating the nociception under acute stress in mice subjected to early-life stress and OTergic and opioidergic systems interact to modulate pain sensitivity in MS mice.Entities:
Keywords: Acute restraint stress; Maternal separation; Opioid; Oxytocin; Pain threshold
Mesh:
Substances:
Year: 2016 PMID: 27932062 DOI: 10.1016/j.npep.2016.11.005
Source DB: PubMed Journal: Neuropeptides ISSN: 0143-4179 Impact factor: 3.286